![]() |
Positive interim results of ARRY-380 in Phase 1 trial announced
Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.
More... |
| All times are GMT -7. The time now is 07:11 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021